• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·PGMN3.SA
Share

Empreendimentos Pague Menos S.A. Stocks

R$ 3.24Last Updated 14.08.2026

Issuer Rating

5/7
Performance

Strong

Risk

Moderate

Recommendation

Hold

Market Cap

R$ 491.69M

R$ 3.24
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Empreendimentos Pague Menos S.A. operates a prominent pharmacy chain across Brazil, offering a comprehensive array of health and wellness products. Their extensive inventory includes a wide variety of medications spanning numerous therapeutic categories such as pain relief, allergy treatment, digestive health, diabetes management, and vitamins. Beyond pharmaceuticals, the company provides a vast selection of personal care and beauty products, dermo-cosmetics, and specialized items for mothers and babies. They also stock general merchandise, including toys, clothing, food, beverages, and various household essentials. Established in 1981 and headquartered in Fortaleza, Brazil, Pague Menos manages a substantial retail network of 1,105 stores throughout the country.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.08.2026 21:00

Anthropic Is Aiming for a Record; Whoop Is Expanding Its Workforce: Key Takeaways on the IPO by August 16

16.08.2026 15:01

A Problem Worth Billions: How Much Is the EU Stock Market Losing Due to Mental Health Disorders?

15.08.2026 16:01

Small caps last week: Playboy's pivot, AbCellera trial win, GLP-1 boon for AirSculpt

15.08.2026 13:01

A New Leader from China, Billionaires in Soccer, and Ray Dalio's Party

15.08.2026 03:06

Alphabet, Delta, and Construction: Where Buffett's Successor Invested

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026